Junichi Hashimoto

Learn More
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity, and recommended starting dose of axitinib in patients with advanced solid tumors. Twelve patients received single-dose axitinib 5 mg and were(More)
Monte-Carlo Tree Search (MCTS) is a very successful approach for improving the performance of game-playing programs. This paper presents the Accelerated UCT algorithm, which overcomes a weakness of MCTS caused by deceptive structures which often appear in game tree search. It consists in using a new backup operator that assigns higher weights to recently(More)
Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors. Methods(More)
This phase I, open-label study investigated the Toll-like receptor 9 agonist, PF-3512676, in combination with carboplatin and paclitaxel in Japanese patients with advanced, non-small-cell lung cancer (NSCLC). Patients (n = 12) with treatment-naive stage IIIB or IV NSCLC received single-agent PF-3512676 subcutaneously once during the first 7 days(More)
  • Neha Bhanushali, Pooja Nikam, +14 authors Kejun Wang
  • 2015
Palm Vein Recognition (PVR) technology uses a near-infrared light to capture a user's palm vein pattern, generating a unique biometric template that is matched against pre-registered users' palm vein patterns. It is a contactless authentication technology that offers an easy-to-use, hygienic solution to verify identity. This advanced, vascular(More)
  • 1